Адъювантная гормонотерапия рака молочной железы длительностью 10 лет: за и против (обзор литературы)
https://doi.org/10.17650/1994-4098-2013-0-3-4-50-53
Аннотация
ЦУ больных гормонально-зависимыми опухолями молочной железы тамоксифен является одним из основных препаратов адъю- вантной гормонотерапии. Целью данной статьи является анализ результатов 7 рандомизированных исследований по длительной адъювантной гормонотерапии рака молочной железы.
Об авторах
С. М. Портной
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия
Россия
Т. А. Шендрикова
ФГБУ «РОНЦ им. Н.Н. Блохина РАМН», Москва
Россия
Россия
Список литературы
1. WHO Statistical Information System (WHOSIS). URL: http://www.who.int/whosis (дата обращения: 24.03.2010).
2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестн РОНЦ 2011;22(3 прил 1):57.
3. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988;319(26):1681–92.
4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451–67.
5. Stewart H.J., Forrest A.P., Everington D. et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74(2):297–9.
6. Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93(6):456–62.
7. Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684–90.
8. Gray R.G., Rea D.W., Handley K. et al. aTTom Collaborators. aTTom (adjuvant Tamoxifen–To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor- positive (ER+) or ER untested breast cancer– Preliminary results. J Clin Oncol 2008;26(15S):513.
9. Gray R.G., Rea D.W., Handley K. et al. aTTom Collaborative Group. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013;31(18S):5.
10. Davies C., Pan H., Godwin J., et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet
11. ;381(9869):805–16.
12. Goss P.E., Ingle J.N., Martino S. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793– 802.
13. Jin H., Tu D., Zhao N. et al. Longerterm outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012;30(7):718–21.
14. Jakesz R., Greil R., Gnant M. et al. Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845–53.
15. Mamounas E.P., Jeong J.H., Wickerham D.L. et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to- treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008;26(12):1965–71.
Рецензия
Для цитирования:
Портной С.М., Шендрикова Т.А. Адъювантная гормонотерапия рака молочной железы длительностью 10 лет: за и против (обзор литературы). Опухоли женской репродуктивной системы. 2013;(3-4):50-53. https://doi.org/10.17650/1994-4098-2013-0-3-4-50-53
For citation:
Portnoy S.M., Shendrikova T.A. Ten-year adjuvant hormone therapy for breast cancer: the pros and cons (a review of literature). Tumors of female reproductive system. 2013;(3-4):50-53. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-3-4-50-53
Просмотров:
779
Послать статью по эл. почте 